

New Study by The University of Utah and Techcyte Demonstrates the Value of AI in Organ Transplantation

How Whole Slide Imaging and AI Can Improve Organ Transplants

OREM, UTAH, USA, February 2, 2023 /EINPresswire.com/ -- A new study published in the Official Journal of The Transplant Society and International Liver Transplantation Society titled ["How Whole Slide Imaging and AI Can Improve Organ Transplants"](#) was authored by the Department of Surgery at the University of Utah and Techcyte. As the clinical pathology AI platform, Techcyte actively participates in research and explores new markets where artificial intelligence (AI) can have a meaningful impact. Techcyte is pleased to have worked with the dedicated organ transplantation team members at the University of Utah on this publication.



Today, many viable organs, particularly kidneys and livers, from deceased donors are more likely to be discarded because transplant biopsy reports are inconsistent, and manual reads of frozen section biopsy slides are labor-intensive. Together, the University of Utah and Techcyte explored whether implementing whole slide imaging and artificial intelligence could address this problem.

"The goal is to give surgeons quick and easy access to images and clinical pathology reports so they can be better-positioned to make time-sensitive decisions on whether or not to accept an organ to be transplanted," said Kim Olechowski, Techcyte Product Manager.

The study concludes, "Whole slide imaging and AI can fill the gaps that negatively impact surgical decision-making and long-term patient outcomes. [AI] technology can improve the quality and accuracy of pre-transplantation biopsy reports, significantly reduce the duration of getting organs to patients, and avoid the transplantation of unviable organs."

Techcyte is delighted with the results of this study. "This is what we're all about," said Ben

Cahoon, Techcyte CEO. "Our mission at Techcyte is to improve people's lives with the digitization and automation of diagnostics through AI. This study is evidence that our mission is becoming a reality."

[Read the study here.](#)

###

About Techcyte

Techcyte, Inc. was founded in 2013 in Orem, Utah and is the world leader in AI-based cellular digital diagnostics. Techcyte's Clinical Pathology AI Platform uses deep machine learning to perform automated analysis of whole slide microscopy images, revolutionizing digital diagnostics for human, animal, and environmental clinics and labs.

Visit techcyte.com for more information.

Techcyte's clinical pathology platform is for Research Use Only in the United States.

Troy Bankhead

Techcyte

+ +1 435 210 6200

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/614663790>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.